“AI is about augmenting ourselves and keeping the human in the centre of the loop”. Kyowa Kirin’s Digital Programme and Customer Experience Director, David Wilson, recently sat down with Inspired Business Media to talk about how AI is revolutionising everyday business operations and customer experiences in pharmaceuticals. Having delivered digital transformation at Kyowa Kirin for three and a half years across Europe and the Middle East, David reflects on the constantly evolving AI journey, the challenges to adopt AI as a tool and how it can help HCPs and patients alike through improving the user experience and offering highly personalised content. Click the link below to watch the full interview. https://lnkd.in/gxqWn-kN #KKIMakingPeopleSmile
Kyowa Kirin International plc.
Pharmaceutical Manufacturing
Galashiels, Selkirkshire 29,713 followers
Kyowa Kirin International | Making people smile | www.KyowaKirinInternational.com
About us
At Kyowa Kirin International (KKI), commitment to life is at our core. We strive to answer the unmet medical needs of patients, their families, and the medical professionals who care for them. With more than 700 people focused on this purpose, we are a rapidly growing specialty biopharmaceutical company, engaged in the development and commercialisation of innovative medicines in the therapy areas of oncology, nephrology and central nervous system (CNS) across Europe and the Middle East. KKI, headquartered in Marlow, England, and Galashiels, Scotland, is owned by Kyowa Kirin Co., Ltd (KKC), of Japan. Founded in 1949, KKC has a successful track record in Japan and has expanded globally. Our history of innovation is built on a strong legacy of scientific discovery and fostering collaborations that accelerate the delivery of innovative medicines to patients. Grounded in our expertise in antibody engineering, we continue to investigate new molecules with the potential to contribute to the future of healthcare and make a difference in the lives of patients. At KKI, it is our people who have helped make a real difference to our success. Working together, our employees excel in achieving results quickly and effectively, bringing diverse and unique viewpoints to the company to achieve our vision. Our passion and energy around our core values of commitment to life, innovation, integrity and teamwork help ensure that every day, each of us is focused on not just making medicines, but also making people smile. With our strong legacy and exciting future, KKI is looking for great people to join our team and support our commitment to life.
- Website
-
http://www.KyowaKirinInternational.com
External link for Kyowa Kirin International plc.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 501-1,000 employees
- Headquarters
- Galashiels, Selkirkshire
- Type
- Privately Held
- Founded
- 1995
- Specialties
- Oncology, Nephrology, Central Nervous System, Biotechnology, Antibodies, Drug Discovery, Clinical Development, Rare Disease, Pharmaceuticals, Specialty Pharmaceuticals, Biopharmaceuticals, Neurology, and Hematology / Haematology
Locations
-
Primary
Galabank Business Park
Galashiels, Selkirkshire TD1 1QH, GB
-
2 Globeside, Fieldhouse Lane
Marlow, Buckinghamshire SL7 1HZ, GB
Employees at Kyowa Kirin International plc.
-
Jacqueline Hoftijzer
Available Sep '24🚀 | Interim (digital) marketeer | brand manager | product manager | project manager | healthcare | pharma | medical devices | life…
-
Victor Kara
VP, Global Head of Digital, Data and AI at Kyowa Kirin USA Holdings Inc.
-
John Strandberg
-
Paolo Fiorini
Director, Global Product Strategy, Business Insights and Analytics
Updates
-
"At Kyowa Kirin, we are guided by the power of Wa – to be in harmony, to celebrate and commemorate LGBTQ+ communities. Stemming from our shared values, Wa represents the thread that binds us, empowering each of us to be our true, authentic selves.” Read more from Jeremy Morgan, a proud ally and advocate for the #LGBTQ+ community, and President of Kyowa Kirin International plc (EMEA) https://lnkd.in/gdy-CfKM #Pride2024 #KKIMakingPeopleSmile
-
We’re thrilled to announce that KKI UAE has recently been certified as a Great Place To Work (GPTW)! The GPTW represents the global authority on workplace culture and employee experience, and is the only recognition programme based on validated employee feedback. At KKI, we like to say that our company is made up of people with brilliant minds and kind hearts, and this comes through in how we work together – that’s why we’re particularly excited about this news! Congratulations to the entire KKI UAE team for their hard work and dedication in achieving this certification. Your contributions have not only made KKI UAE a great place to work but also a place where happiness and satisfaction are a priority. #KKIMakingPeopleSmile #GPTWcertified
-
Following her presentation at the 5th Annual Patient Centricity and Engagement Conference in London last month, Angela Rylands PhD CPyschol, Global Patient Reported Outcomes (PRO) Expert Lead at Kyowa Kirin International (KKI), reflects on the vital role of patients and carers as partners in the design of real-world studies using PROs. Read the article below to learn more about the presentation and KKI’s ongoing work efforts to work with patients and carers as partners. #KKIMakingPeopleSmile
-
Last month, Kyowa Kirin hosted its inaugural CTCL Forum in Madrid, Spain, with the theme ‘The Power of Connections’. It brought together 10 leading CTCL experts with 90 clinicians from 20 countries to network, share knowledge, and exchange ideas. We’re committed to addressing the significant unmet needs in CTCL, and hope the connections made during the Forum will help drive substantial progress for those living with this rare condition. Thank you to everyone who participated! This meeting was organised and funded by Kyowa Kirin. #KKIMakingPeopleSmile #CutaneousTCellLymphoma
-
While there has undoubtedly been progress since the first #Pride marches in the 1970s, we recognise that members of the LGBTQ+ community still face discrimination around the world. At Kyowa Kirin, we stand as allies to create visibility, understanding and acceptance. 👉 Hear from our LGBTQ+ community members and allies from across our global team. #Pride2024 #LGBTQ+ #KKIMakingPeopleSmile
-
We were delighted to welcome Laurence Peyraut, CEO of the French Pharmaceutical Companies Association (Leem), our CEO Masashi Miyamoto, and KKI’s President Jeremy Morgan to our Kyowa Kirin Paris office last month. Leem brings together companies across the healthcare sector to collaborate and share our passion for patients. The meeting was a valuable opportunity to discuss some critical topics about the future of the pharmaceutical industry, including: 🌠 Driving excellence in patient care and scientific innovation in rare diseases 🚀 Attracting talent to our industry to drive innovation 🌿 Accelerating the sustainable transformation of the sector We are grateful to Laurence Peyraut and Leem for their partnership and shared vision, and look forward to continued collaboration with partners across the region to help bring more smiles to patients. #KKIMakingPeopleSmile
-
In today’s rapidly evolving healthcare landscape, Medical Affairs plays a crucial role in communicating complexity across the treatment pathway. Danie du Plessis, EVP Pharmaceutical Operations at KKI, recently shared his perspectives on this with The Pharma Letter, including: 📢 The vital role of Medical Affairs in sharing complex information across audiences and channels 🔬 How Medical Affairs is keeping pace with scientific innovation to unlock greatest patient benefits 📈 How the function is growing rapidly to meet the changing needs of stakeholders Read the full article below! #KKIMakingPeopleSmile #MedicalAffairs
-
Following her presentation at the Patients as Partners conference last month, Emily Hardie, Senior Clinical Research Associate at Kyowa Kirin International, reflects on the vital role of patient collaboration in the design of real-world observational studies. Read the article below to learn more about the presentation and KKI’s ongoing collaboration with Susan Thornton and the Cutaneous Lymphoma Foundation, to advance research and improve patient care in cutaneous T-cell lymphoma (CTCL).
Leveraging Patient and Public Involvement to Enhance Real-World Study Design
Kyowa Kirin International plc. on LinkedIn
-
We recently marked World Environment Day – a crucial moment for us to consider how we can better protect our environment for future generations. 🌍 At KKI, we know that to serve the health of people, we must also ensure that our business practices support a healthy planet. As part of our commitment to environmental sustainability, we have launched a new e-learning course for all KKI employees to learn about the steps we’re taking: 🌟 UN Sustainable Development Goals (SDGs): Kyowa Kirin is committed to the UN SDGs, including a reduction in CO₂ emissions by 55% for 2030, compared to 2019 levels 🔌 Shift to renewable energy: Since 2020, we have shifted to renewable energy for all purchased electric power at our plants and labs across Japan 🌿 Greenhouse gas emissions: At KKI, we have conducted a baseline assessment of our emissions and are developing a plan to reduce them Together, we can take care of our planet and the wellbeing of future generations. #KKIMakingPeopleSmile #WorldEnvironmentDay